Skip to main content
Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model
Antimicrobial Agents and Chemotherapy (2004)
  • R. P. Iyer
  • A. Roland
  • Y. Jin
  • S. Mounir
  • B. Korba
  • Justin G. Julander, Utah State University
  • John D. Morrey, Utah State University
ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P <= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.
  • anti hepatitis b,
  • virus activity,
  • ORI-9020,
  • phosphorothioate,
  • dinucleotide,
  • transgenic,
  • mouse
Publication Date
January 1, 2004
Citation Information
Iyer, R.P., A. Roland, Y. Jin, S. Mounir, B. Korba, J.G. Julander, and J.D. Morrey 2004. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model Antimicrobial Agents and Chemotherapy 48(6): 2318-2320.